The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (13 analysts) rates it hold, with a mean price target of $201.
Gartner
IT · a US exchange · USD · Market cap $12.2B · 19,367 employees
Gartner, Inc.
FAIL · Does not pass the screenPrice as of 17 Nov 2026Daily close, not a live quote
Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price183.47 USD at the 17 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 17 Nov 2026
- Our regime readDistribution, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 2.47)
- Last reviewed17 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $231.00 to $384.30, base estimate $231.00 (screen dated 2026-11-17).
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning political buying, disclosed 2026-10-13
- Options put/call open interest 2.47, read 2026-11-14
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Gartner holds its Distribution at $183.47. The statistical read favours the buyers, held for 3 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the buyers, held for 3 days |
| Price at the screen | $183.47 |
| Valuation | 13.83 trailing · 11.61 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 0.91 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 41.41% | Below 33% | Interest-bearing debt is 41.4% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 42.14% | Below 49% | Money owed to the company is 42.1% of assets, under the 49% limit. | Pass |
| Revenue purity | 1.00% | Below 5% | Only 1.0% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Gartner's business is in a permissible area, but its interest-bearing debt is about 41% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when IT's ethical verdict changes
Today IT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 17 Nov 2026: it trades at roughly a 21% discount to our $231.00 fair value, moderate competitive moat.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. A 20.6% discount to the base estimate.
Third-party analyst targets: 13 covering, consensus Hold. The average target sits +8% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $231.00, with a range of $231.00 to $384.30, dated to the 2026-11-17 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsGartner looks cheap until the debt bites
Executives pay Gartner for the research that shapes their next big move, yet the company carries more debt than its ethical screen allows. We pass, even though the shares sit well below our own fair value and the forward multiple looks modest at 9.2 times.
Revenue fell 2 percent last year while margins held at 11 percent and return on equity reached 95 percent. The moderate moat and hold-rated analyst target of 164 dollars suggest the business is stable, but none of that overrides the debt-ratio failure.
High returns can mask leverage that leaves little room when cycles turn. Currency moves and conference demand swings add further pressure that the numbers do not fully capture. Analysis, not advice.
| Forward P/E | 11.6xreasonably valued |
| Trailing P/E | 13.8xreasonably valued |
| EPS, trailing | 13.96 |
| EPS, forward | 16.62 |
| Revenue growth | -1.3%revenue is shrinking |
| Profit margin | 14.8%thin but positive margins |
| Return on equity | 365.8%an exceptional return on shareholder capital |
| FCF yield | 8.77% |
| Current ratio | 0.91below 1: short-term bills exceed liquid assets |
| Beta | 0.91steadier than the market |
| Short interest, float | 0.14% |
| 52-week range | 124.25 - 256.90 |
| Moat | MODERATE |
| Market cap | $12.2B |
| Employees | 19,367 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeIT trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 16.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (13 analysts) rates it hold, with a mean price target of $201.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (13 analysts) rates it hold, with a mean price target of $194. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (13 analysts) rates it hold, with a mean price target of $194. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (13 analysts) rates it hold, with a mean price target of $194. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (13 analysts) rates it hold, with a mean price target of $194. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (13 analysts) rates it hold, with a mean price target of $194. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (13 analysts) rates it hold, with a mean price target of $194. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (13 analysts) rates it hold, with a mean price target of $194. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 63%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (13 analysts) rates it hold, with a mean price target of $194. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- CoreWeave Stock Surges as Revenue Soars. Is It Too Late to Buy the Stock? Yahoo Finance · 4d ago
- What Does D Wave Quantum's (QBTS) Gartner Recognition Mean For Its Stock? Yahoo Finance · 5d ago
- Cloudflare Placed in 2026 Gartner® Magic Quadrant™ for Edge Distribution Platforms Yahoo Finance · 5d ago
- Revenium Recognized as a Market Shaper in the 2026 Gartner® Emerging Market Quadrant for AI FinOps Tools — Startup Vendors Yahoo Finance · 6d ago
- Super Micro Slides 7% Despite Gartner’s $957 Billion AI Server Forecast; Dell Falls 4%, Hewlett Packard Enterprise Dips Yahoo Finance · 6d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-04 | KIM THOMAS SANG | Officer | 1,130 | · | |
| 2026-03-11 | GRABE WILLIAM O | Director | 1,880 | · | |
| 2026-02-09 | HALL EUGENE A. | Chief Executive Officer | 16,729 | · | |
| 2026-02-09 | KRANICH ROBIN B. | Officer | 2,925 | · | |
| 2026-02-09 | JAIN AKHIL | Officer | 1,868 | · | |
| 2026-02-09 | WARTINBEE WILLIAM JAMES III | Officer | 797 | · | |
| 2026-02-09 | RINELLO JOHN J | Officer | 447 | · | |
| 2026-02-09 | VAN HAM DICK | Officer | 337 | · | |
| 2026-02-09 | HERKES CLAIRE L | Officer | 1,868 | · | |
| 2026-02-09 | GENOVESE YVONNE | Officer | 1,868 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-11-04 | Gil Cisneros | Democrat | buy | 250K–500K |
| 2026-10-27 | Gil Cisneros | Democrat | sell | 1K–15K |
| 2026-10-23 | Gil Cisneros | Democrat | buy | 250K–500K |
| 2026-10-20 | Gil Cisneros | Democrat | buy | 1K–15K |
| 2026-10-20 | Gil Cisneros | Democrat | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $153.80 | +1.2% | · | $1,012 | +1.2% |
| 2 months | $143.72 | +8.3% | · | $1,083 | +8.3% |
| 3 months | $160.59 | -3.1% | · | $969 | -3.1% |
| 6 months | $232.66 | -33.1% | · | $669 | -33.1% |
| 1 year | $422.48 | -63.2% | · | $368 | -63.2% |
| 2 years | $436.30 | -64.3% | · | $357 | -64.3% |
| 3 years | $344.55 | -54.9% | · | $452 | -54.9% |
| 5 years | $232.99 | -33.2% | · | $668 | -33.2% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever IT does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.